NCT04627428
Safety and Tolerability of RPESC-derived RPE Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)
A Phase1/2a, Open-Label Study to Evaluate the Safety and Tolerability of RPESC-derived RPE Transplantation as Therapy for Dry Age-related Macular Degeneration (AMD)
Luxa Biotechnology, LLC·Phase 1/2·ClinicalTrials.gov·biologicalNot yet recruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Dry Age-related Macular Degeneration
- Drug/Device/Intervention
- RPESC-RPE-4W
- Study type
- Interventional
- Intervention type
- biological
Sponsor & location
- Primary sponsor
- Luxa Biotechnology, LLC
- Location
- Ann Arbor, United States of America
Timeline & enrollment
- Phase
- Phase 1/2
- Start date
- Feb 01, 2022
- End date
- Sep 01, 2025
- Enrollment
- 18 participants
Primary outcome
Safety and tolerability of RPESC-RPE-4W transplantation
Summary
The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W
 as therapy for dry AMD.
ICD-10 classifications
Peripheral retinal degenerationCorneal degenerationHereditary retinal dystrophyOptic atrophy in diseases classified elsewhereDisorders of choroid and retina
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT04627428
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT04627428 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Luxa Biotechnology, LLC and is currently Not yet recruiting. The study focuses on Dry Age-related Macular Degeneration. Target enrollment is 18 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.